3 results
Approved WMOCompleted
The primary objective is to evaluate the safety and efficacy of the PulseCath iVAC2L in highriskPCI patients who require left ventricular assistance. Safety will be assessed by theincidence of Cerebrovascular Accidents (CVA*s), thrombo-embolic…
Approved WMOCompleted
Evaluate the effects of CER-001 - adminstered as iv infusion - on plaque size/burden in arteries, plaque inflammation in the artery wall and the rate of cholesterol transport in the body
Approved WMOCompleted
To assess the impact of 10 intravenous infusions of 3 mg/kg CER-001 versus placebo, given at weekly intervals, on atherosclerotic plaque volume, as measured by coronary IVUS, when administered to subjects presenting with an ACS event.